Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040404 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
A Phase 2 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 2
- Development phase
- 806
- Enrollment target
NCT00040404 is a Phase 2 study that was terminated before completion, run by Cephalon. The registered enrollment target is 806 participants.
The verdict
NCT00040404, a Phase 2 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 806 participants
- Enrollment target
Study Summary
The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
Interventions
- OTHER Placebo Comparator
- DRUG CEP-1347 10mg
- DRUG CEP1347 25mg
- DRUG CEP-1347 50mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 806 participants |
| Start Date | 2002-03 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040404
The ClinicalTrials.gov registry entry for NCT00040404 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 806 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Comparator is the first listed.
NCT00040404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040404 about?
NCT00040404 is a clinical study titled "Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease". The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
What is the current status of trial NCT00040404?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 806 participants. The study started on 2002-03. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00040404?
The interventions under investigation include: Placebo Comparator (OTHER), CEP-1347 10mg (DRUG), CEP1347 25mg (DRUG), CEP-1347 50mg (DRUG).
Who is sponsoring clinical trial NCT00040404?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.